Alkermes (ALKS): Can the Stock Clear $60 After Its Strong Rally?
Key Takeaways
- The selected price target is $60 per share, a round-number level roughly 22% above the most recent close of $49.06 and above the 52-week high of $55.67.
- The strongest bullish factors include positive Phase 2 data for the orexin candidate alixorexton, the Avadel/LUMRYZ sleep-franchise acquisition, and multiple analyst targets at or above $60.
- The biggest obstacles are a stretched valuation after a powerful rally, intensifying competition in sleep medicine, and the inherent risk of late-stage clinical development.
- Key technical levels include support in the upper $40s and resistance first at $55.67, followed by the psychological $60 zone.
- For investors, $60 appears achievable only if pipeline catalysts continue to deliver and the stock clears its 52-week high on meaningful volume.
Why the $60 Level Stands Out
Alkermes plc (NASDAQ: ALKS) has drawn steady attention in the neuroscience and sleep-medicine sector. With U.S. markets closed for the weekend, the latest regular-session close stood at $49.06 on August 14, 2026. The shares have risen roughly 75% year to date from a 52-week low of $25.17, yet they still sit below the 52-week high of $55.67 reached in early July.
The $60 stock price target sits just above that prior peak and just below several bullish Wall Street estimates. It therefore represents a natural, frequently discussed milestone: a decisive break above $60 would indicate the rally rests on more than a single catalyst.
Company Snapshot and Market Position
Alkermes is a Dublin-based biopharmaceutical company whose commercial portfolio includes LYBALVI, ARISTADA, ARISTADA INITIO and VIVITROL, treatments for schizophrenia, bipolar I disorder and alcohol or opioid dependence. The company has moved into sleep medicine via its acquisition of Avadel and the once-nightly sodium oxybate product LUMRYZ.
First-quarter 2026 results demonstrated commercial resilience: revenue of $392.9 million topped expectations of roughly $362.9 million, while the reported loss per share of $0.40 came in narrower than the anticipated $0.54. Full-year 2026 revenue is projected to expand meaningfully, backed by both the legacy psychiatry franchise and the newer sleep portfolio.
Pipeline Catalysts That Could Lift the Stock
The core bull case centers on the orexin pipeline. Alkermes is advancing alixorexton, an orexin 2 receptor agonist under study in narcolepsy and idiopathic hypersomnia. Phase 2 VIBRANCE-2 results in narcolepsy type 2 delivered statistically significant improvements in wakefulness and reductions in excessive daytime sleepiness, prompting several analyst target increases in June and July. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Additional readouts remain on the calendar. Investors are awaiting Phase 2 VIBRANCE-3 data in idiopathic hypersomnia and early data for ALKS 7290 in ADHD, both expected in the fourth quarter of 2026. Meanwhile, the Phase 3 REVITALYZ study of LUMRYZ in idiopathic hypersomnia met its primary endpoint, reinforcing the commercial case for the Avadel acquisition.
Key Risks That Could Limit Upside
Valuation remains the most commonly cited concern. After a gain of roughly 55% over a three-month stretch into July, some firms contend that much of the orexin opportunity is already priced in. BofA Securities maintains a Sell rating with a $38 target, while H.C. Wainwright stays Neutral with a $43 target. JPMorgan holds a Neutral rating and a $61 target, noting that competitive and execution risks persist.
Competition is increasing. Takeda’s orexin candidate oveporexton is progressing in narcolepsy type 1, and Eli Lilly’s announced acquisition of orexin-focused Centessa points to deeper rivalry. Generic erosion in the sodium oxybate market also poses a commercial challenge for LUMRYZ. Recent insider selling has added a cautious note, although it remains modest relative to overall institutional ownership.
Important Technical Levels
The long-term trend for ALKS remains upward, with the stock forming higher lows since late 2025. The first major resistance level is the 52-week high of $55.67; a convincing breakout above that area would open a path toward the round-number $60 zone.
On the downside, support rests in the upper $40s, roughly aligned with the rising 50-day moving average, with a deeper demand zone near the mid-$40s. The 200-day moving average, near $38, marks the longer-term trend line that has contained pullbacks during this advance.
Analyst Views and Price Targets
Wall Street stays generally constructive, with a consensus Buy or Moderate Buy rating and an average analyst price target near $56. The range is unusually wide: from a low of $38 to a high of $72. Recent targets cluster around the $60 threshold, including $61 at JPMorgan, $62 at Needham, $63 at Stifel, and $65 at Mizuho, Jefferies and Wells Fargo. That places $60 between the consensus average and the more bullish end of the Street’s forecast range, rendering it a credible yet not guaranteed objective.
Integrating AI Daily Buy/Sell Signals
I find Tickeron’s AI Daily Buy/Sell Signals helpful for tracking evolving technical and market signals on names like ALKS. The tool uses artificial intelligence to monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on changing conditions and AI-driven analysis. It serves as a complement to personal research and risk management rather than a replacement.
Final Assessment
A move to $60 appears realistic but not assured. The strongest support comes from a productive clinical pipeline, the Avadel/LUMRYZ expansion, and several analyst targets at or above that level. The principal risks are valuation, competitive pressure in orexin-based sleep medicine, and the normal uncertainty of late-stage drug development. Before $60 can become sustainable, ALKS would likely need to clear the $55.67 resistance level, deliver positive fourth-quarter pipeline data, and avoid deterioration in the broader biotech tape. Investors should monitor clinical readouts, LUMRYZ commercialization, competitor announcements, and whether the stock can hold the upper $40s on any pullback.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
ALKS in +1.48% Uptrend, advancing for three consecutive days on September 17, 2026
Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where ALKS advanced for three days, in 203 of 278 cases, the price rose further within the following month. The odds of a continued upward trend are 73%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where ALKS's RSI Indicator exited the oversold zone, 14 of 20 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 70%.
The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.
ALKS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on August 26, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ALKS as a result. In 65 of 101 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 64%.
The Moving Average Convergence Divergence Histogram (MACD) for ALKS turned negative on September 18, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 45 similar instances when the indicator turned negative. In 24 of the 45 cases the stock turned lower in the days that followed. This puts the odds of success at 53%.
ALKS moved below its 50-day moving average on August 20, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ALKS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 64%.
The Aroon Indicator for ALKS entered a downward trend on September 21, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 2 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 35 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 82, placing this stock slightly better than average.
The Tickeron Price Growth Rating for this company is 44 (best 1 - 100 worst), indicating steady price growth. ALKS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 85 (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 99 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.024) is normal, around the industry mean (43.618). P/E Ratio (114.184) is within average values for comparable stocks, (141.316). ALKS's Projected Growth (PEG Ratio) (21.570) is very high in comparison to the industry average of (2.181). Dividend Yield (0.000) settles around the average of (0.005) among similar stocks. P/S Ratio (4.638) is also within normal values, averaging (178.797).
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a manufacturer of pharmaceutical products
Industry PharmaceuticalsGeneric
Advertisement